Secondary dyslipidaemia

References

• O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993; 68(9): 860–866.
   PubMed Web of Science ®Google Scholar
• Soutar AK, Knight BL. Structure and regulation of the LDL-receptor and its gene. Br Med Bull 1990; 46(4): 891–916.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Byrnes P, Jones S, Marais AD. Dysbetalipoproteinaemia—clinical and pathophysiological features. S Afr Med J 2002; 92(11): 892–897.
   PubMed Web of Science ®Google Scholar
• Valdemarsson S, Hansson P, Hedner P, Nilsson-Ehle P. Relations between thyroid function, hepatic and lipoprotein lipase activities, and plasma lipoprotein concentrations. Acta Endocrinol (Copenh) 1983; 104(1): 50–56.
   PubMedGoogle Scholar
• Prieur X, Huby T, Coste H, Schaap FG, Chapman MJ, Rodriguez JC. Thyroid hormone regulates the hypotriglyceridemic gene APOA5. J Biol Chem 2005; 280(30): 27533–27543.
   PubMed Web of Science ®Google Scholar
• Tan KC, Shiu SW, Kung AW. Effect of thyroid dysfunction on high-density lipoprotein subfraction metabolism: roles of hepatic lipase and cholesteryl ester transfer protein. J Clin Endocrinol Metab 1998; 83(8): 2921–2924.
   PubMed Web of Science ®Google Scholar
• Tan KC, Shiu SW, Kung AW. Plasma cholesteryl ester transfer protein activity in hyper- and hypothyroidism. J Clin Endocrinol Metab 1998; 83(1): 140–143.
   PubMed Web of Science ®Google Scholar
• Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009; 150(12): 858–868.
   PubMed Web of Science ®Google Scholar
• Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab 2005; 90(1): 581–585.
   PubMed Web of Science ®Google Scholar
• Duntas LH, Wartofsky L. Cardiovascular risk and subclinical hypothyroidism: focus on lipids and new emerging risk factors. What is the evidence? Thyroid 2007; 17(11): 1075–1084.
   PubMed Web of Science ®Google Scholar
• McDermott MT, Ridgway EC. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab 2001; 86(10): 4585–4590.
   PubMed Web of Science ®Google Scholar
• Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000; 85(9): 2993–3001.
   PubMed Web of Science ®Google Scholar
• Perez A, Cubero JM, Sucunza N et al. Emerging cardiovascular risk factors in subclinical hypothyroidism: lack of change after restoration of euthyroidism. Metabolism 2004; 53(11): 1512–1515.
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Meier C, Guglielmetti M et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 2003; 166(2): 379–386.
   PubMed Web of Science ®Google Scholar
• Rodondi N, den Elzen WP, Bauer DC et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010; 304(12): 1365–1374.
   PubMed Web of Science ®Google Scholar
• Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest 2006; 116(7): 1813–1822.
   PubMed Web of Science ®Google Scholar
• Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53(3): 298–304.
   PubMed Web of Science ®Google Scholar
• Standards of medical care in diabetes—2010. Diabetes Care 2010; 33 Suppl 1:S11–S61.
   PubMedGoogle Scholar
• Nicholls SJ, Lundman P, Tardif JC. Diabetic dyslipidemia: extending thetarget beyond LDL cholesterol. Eur J Cardiovasc Prev Rehabil 2010; 17 Suppl 1:S20–S24.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1563–1574.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks FM, Hermans MP. Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). Curr Med Res Opin 2010; 26(8): 1793–1797.
   PubMed Web of Science ®Google Scholar
• Tenenbaum A, Fisman EZ. “If it ain't broke, don't fix it”: a commentary on the positive-negative results of the ACCORD Lipid study. Cardiovasc Diabetol 2010; 9: 24.
   PubMed Web of Science ®Google Scholar
• Judge EP, Phelan D, O'Shea D. Beyond statin therapy: a review of the management of residual risk in diabetes mellitus. J R Soc Med 2010; 103(9): 357–362.
   PubMed Web of Science ®Google Scholar
• Albiger N, Testa RM, Almoto B et al. Patients with Cushing's syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. Horm Metab Res 2006; 38(6): 405–410.
   PubMed Web of Science ®Google Scholar
• Fallo F, Sonino N. Should we evaluate for cardiovascular disease in patients with Cushing's syndrome? Clin Endocrinol (Oxf) 2009.
   Google Scholar
• De Leo M, Pivonello R, Auriemma RS et al. Cardiovascular disease in Cushing's syndrome: heart versus vasculature. Neuroendocrinology 2010; 92 Suppl 1: 50–54.
   PubMed Web of Science ®Google Scholar
• Clayton RN. Mortality in Cushing's disease. Neuroendocrinology 2010; 92 Suppl 1: 71–76.
   PubMed Web of Science ®Google Scholar
• Lacquaniti A, Bolignano D, Donato V, Bono C, Fazio MR, Buemi M. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney Blood Press Res 2010; 33(2): 100–110.
   PubMed Web of Science ®Google Scholar
• Vaziri ND. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int 2003; 63(5): 1964–1976.
   PubMed Web of Science ®Google Scholar
• Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006; 290(2): F262–F272.
   PubMed Web of Science ®Google Scholar
• Nanayakkara PW, Gaillard CA. Vascular disease and chronic renal failure: new insights. Neth J Med 2010; 68(1): 5–14.
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181–2192.
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353(3): 238–248.
   PubMed Web of Science ®Google Scholar
• Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360(14): 1395–1407.
   PubMed Web of Science ®Google Scholar
• Ritland S. The abnormal “lipoprotein of cholestasis”, lipoprotein-X. Scand J Gastroenterol 1975; 10(8): 785–789.
   PubMed Web of Science ®Google Scholar
• Narayanan S. Lipoprotein-X. CRC Crit Rev Clin Lab Sci 1979; 11(1): 31–51.
   PubMed Web of Science ®Google Scholar
• Chang PY, Lu SC, Su TC et al. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res 2004; 45(11): 2116–2122.
   PubMed Web of Science ®Google Scholar
• Black DD. Chronic cholestasis and dyslipidemia: what is the cardiovascular risk? J Pediatr 2005; 146(3): 306–307.
   PubMed Web of Science ®Google Scholar
• Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007; 194(2): 293–299.
   PubMed Web of Science ®Google Scholar
• Fernandez-Miranda C, De La CM, Larumbe S et al. Lipoprotein abnormalities in patients with asymptomatic acute porphyria. Clin Chim Acta 2000; 294(1–2): 37–43.
   PubMed Web of Science ®Google Scholar
• Stein JA, Tschudy DP. Acute intermittent porphyria. A clinical and biochemical study of 46 patients. Medicine (Baltimore) 1970; 49(1): 1–16.
   PubMed Web of Science ®Google Scholar
• Whitelaw AG. Acute intermittent porphyria, hypercholesterolaemia, and renal impairment. Arch Dis Child 1974; 49(5): 406–407.
   PubMed Web of Science ®Google Scholar
• Mustajoki P, Nikkila EA. Serum lipoproteins in asymptomatic acute porphyria: no evidence for hyperbetalipoproteinemia. Metabolism 1984; 33(3): 266–269.
   PubMed Web of Science ®Google Scholar
• Taddeini L, Frantz I, Jr., Sanghvi A. Acceleration of hepatic sterol synthesis after a single dose of the porphyrogenic chemical allylisopropylacetamide. J Lipid Res 1974; 15(1): 84–88.
   PubMed Web of Science ®Google Scholar
• Sanchez-Muniz FJ, Marcos A, Varela P. Serum lipids and apolipoprotein B values, blood pressure and pulse rate in anorexia nervosa. Eur J Clin Nutr 1991; 45(1): 33–36.
   PubMed Web of Science ®Google Scholar
• Mehler PS, Lezotte D, Eckel R. Lipid levels in anorexia nervosa. Int J Eat Disord 1998; 24(2): 217–221.
   PubMed Web of Science ®Google Scholar
• Weinbrenner T, Zuger M, Jacoby GE et al. Lipoprotein metabolism in patients with anorexia nervosa: a case-control study investigating the mechanisms leading to hypercholesterolaemia. Br J Nutr 2004; 91(6): 959–969.
   PubMed Web of Science ®Google Scholar
• Favaro A, Caregaro L, Di Pascoli L, Brambilla F, Santonastaso P. Total serum cholesterol and suicidality in anorexia nervosa. Psychosom Med 2004; 66(4): 548–552.
   PubMed Web of Science ®Google Scholar
• Matzkin VB, Geissler C, Coniglio R, Selles J, Bello M. Cholesterol concentrations in patients with Anorexia Nervosa and in healthy controls. Int J Psychiatr Nurs Res 2006; 11(2): 1283–1293.
   PubMedGoogle Scholar
• Matzkin V, Slobodianik N, Pallaro A, Bello M, Geissler C. Risk factors for cardiovascular disease in patients with anorexia nervosa. Int J Psychiatr Nurs Res 2007; 13(1): 1531–1545.
   PubMedGoogle Scholar
• Rigaud D, Tallonneau I, Verges B. Hypercholesterolaemia in anorexia nervosa: frequency and changes during refeeding. Diabetes Metab 2009; 35(1): 57–63.
   PubMed Web of Science ®Google Scholar
• Ohwada R, Hotta M, Oikawa S, Takano K. Etiology of hypercholesterolemia in patients with anorexia nervosa. Int J Eat Disord 2006; 39(7): 598–601.
   PubMed Web of Science ®Google Scholar
• Monteleone P, Santonastaso P, Pannuto M et al. Enhanced serum cholesterol and triglyceride levels in bulimia nervosa: relationships to psychiatric comorbidity, psychopathology and hormonal variables. Psychiatry Res 2005; 134(3): 267–273.
   PubMed Web of Science ®Google Scholar
• Reiss AB. Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus. Curr Rheumatol Rep 2009; 11(4): 255–260.
   PubMedGoogle Scholar
• Haque S, Bruce IN. Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat Clin Pract Cardiovasc Med 2005; 2(8): 423–430.
   PubMedGoogle Scholar
• Borba EF, Carvalho JF, Bonfa E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin Dev Immunol 2006; 13(2–4): 203–208.
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon M. Atherosclerosis and systemic lupus erythematosus: the role of altered lipids and of autoantibodies. Lupus 2008; 17(5): 368–370.
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74(5): 1045–1052.
   PubMed Web of Science ®Google Scholar
• Basaran A. Pregnancy-induced hyperlipoproteinemia: review of the literature. Reprod Sci 2009; 16(5): 431–437.
   PubMed Web of Science ®Google Scholar
• Hosokawa A, Bar-Oz B, Ito S. Use of lipid-lowering agents (statins) during pregnancy. Can Fam Physician 2003; 49: 747–749.
   PubMed Web of Science ®Google Scholar
• Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 2004; 131(3): 287–298.
   PubMed Web of Science ®Google Scholar
• Zhai F, Wang H, Du S et al. Prospective study on nutrition transition in China. Nutr Rev 2009; 67 Suppl 1:S56–S61.
   PubMed Web of Science ®Google Scholar
• Kang WM, Zhang JS, Liu XX, Wang MS, Zhao ML, Yu JC. Prevalence of abnormity of blood lipid and associated factors in health examination population in Beijing. Chin Med Sci J 2009; 24(3): 142–146.
   PubMedGoogle Scholar
• Ordovas JM, Schaefer EJ. Genes, variation of cholesterol and fat intake and serum lipids. Curr Opin Lipidol 1999; 10(1): 15–22.
   PubMed Web of Science ®Google Scholar
• Ordovas JM, Galluzzi JR. Genetic predictors of plasma lipid response to diet intervention. Curr Atheroscler Rep 1999; 1(3): 196–203.
   PubMedGoogle Scholar
• Tamasawa N, Murakami H, Yamato K, Matsui J, Tanabe J, Suda T. Influence of apolipoprotein E genotype on the response to caloric restriction in type 2 diabetic patients with hyperlipidaemia. Diabetes Obes Metab 2003; 5(5): 345–348.
   PubMed Web of Science ®Google Scholar
• Knopp RH, Paramsothy P, Retzlaff BM et al. Gender differences in lipoprotein metabolism and dietary response: basis in hormonal differences and implications for cardiovascular disease. Curr Atheroscler Rep 2005; 7(6): 472–479.
   PubMedGoogle Scholar
• Lindberg ML, Amsterdam EA. Alcohol, wine, and cardiovascular health. Clin Cardiol 2008; 31(8): 347–351.
   PubMed Web of Science ®Google Scholar
• Sasaki S. Alcohol and its relation to all-cause and cardiovascular mortality. Acta Cardiol 2000; 55(3): 151–156.
   PubMed Web of Science ®Google Scholar
• Brinton EA. Effects of ethanol intake on lipoproteins and atherosclerosis. Curr Opin Lipidol 2010; 21(4): 346–351.
   PubMed Web of Science ®Google Scholar
• Robinson SF, Quarfordt SH. The effect of ethanol on lipoprotein metabolism. Alcohol Clin Exp Res 1981; 5(1): 101–109.
   PubMed Web of Science ®Google Scholar
• Gepner AD, Piper ME, Johnson HM, Fiore MC, Baker TB, Stein JH. Effects of smoking and smoking cessation on lipids and lipoproteins: Outcomes from a randomized clinical trial. Am Heart J 2011; 161(1): 145–151.
   PubMed Web of Science ®Google Scholar
• Vu-Dac N, Gervois P, Torra IP et al. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids. J Clin Invest 1998; 102(3): 625–632.
   PubMed Web of Science ®Google Scholar
• McLane J. Analysis of common side effects of isotretinoin. J Am Acad Dermatol 2001; 45(5): S188–S194.
   PubMed Web of Science ®Google Scholar
• Greene JP. An adolescent with abdominal pain taking isotretinoin for severe acne. South Med J 2006; 99(9): 992–994.
   PubMed Web of Science ®Google Scholar
• Barbaro G, Iacobellis G. Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr Diab Rep 2009; 9(1): 37–42.
   PubMed Web of Science ®Google Scholar
• Bevilacqua M, Dominguez LJ, Barbagallo M. Insulin Resistance and the cardiometabolic syndrome in HIV infection. J Cardiometab Syndr 2009; 4(1): 40–43.
   PubMedGoogle Scholar
• Moreno S, Miralles C, Negredo E et al. Disorders of body fat distribution in HIV-1-infected patients. AIDS Rev 2009; 11(3): 126–134.
   PubMed Web of Science ®Google Scholar
• Villarroya F, Domingo P, Giralt M. Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment. Biochim Biophys Acta 2010; 1801(3): 392–399.
   PubMed Web of Science ®Google Scholar
• den Boer MA, Berbee JF, Reiss P et al. Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. Arterioscler Thromb Vasc Biol 2006; 26(1): 124–129.
   PubMed Web of Science ®Google Scholar
• Lee GA, Seneviratne T, Noor MA et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004; 18(4): 641–649.
   PubMed Web of Science ®Google Scholar
• Perry RC, Cushing HE, Deeg MA, Prince MJ. Ritonavir, triglycerides, and pancreatitis. Clin Infect Dis 1999; 28(1): 161–162.
   PubMed Web of Science ®Google Scholar
• Bonnet F, Balestre E, Thiebaut R et al. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999–2001. HIV Med 2004; 5(3): 133–139.
   PubMed Web of Science ®Google Scholar
• Winston A, Boffito M. The management of HIV-1 protease inhibitor pharmacokinetic interactions. J Antimicrob Chemother 2005; 56(1): 1–5.
   PubMed Web of Science ®Google Scholar
• McKillop G, Ballantyne D. Lipoprotein analysis in bodybuilders. Int J Cardiol 1987; 17(3): 281–288.
   PubMed Web of Science ®Google Scholar
• Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch Intern Med 1991; 151(10): 1925–1933.
   PubMed Web of Science ®Google Scholar
• Henneman P, Schaap FG, Rensen PC, van Dijk KW, Smelt AH. Estrogen induced hypertriglyceridemia in an apolipoprotein AV deficient patient. J Intern Med 2008; 263(1): 107–108.
   PubMed Web of Science ®Google Scholar
• Lee J, Goldberg IJ. Hypertriglyceridemia-induced pancreatitis created by oral estrogen and in vitro fertilization ovulation induction. J Clin Lipidol 2008; 2(1): 63–66.
   PubMed Web of Science ®Google Scholar
• Deshmukh M, Lee HW, McFarlane SI, Whaley-Connell A. Antihypertensive medications and their effects on lipid metabolism. Curr Diab Rep 2008; 8(3): 214–220.
   PubMed Web of Science ®Google Scholar
• Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J 2000; 139(1 Pt 1): 174–183.
   PubMed Web of Science ®Google Scholar
• Marchetti P, Navalesi R. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest 2000; 23(7): 482–490.
   PubMed Web of Science ®Google Scholar
• Zheng XL, Wong NC. Cyclosporin A inhibits apolipoprotein Al gene expression. J Mol Endocrinol 2006; 37(2): 367–373.
   PubMed Web of Science ®Google Scholar
• Morrisett JD, Abdel-Fattah G, Hoogeveen R et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43(8): 1170–1180.
   PubMed Web of Science ®Google Scholar
• Firpi RJ, Tran TT, Flores P et al. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. Aliment Pharmacol Ther 2004; 19(9): 1033–1039.
   PubMed Web of Science ®Google Scholar
• Koponen H, Saari K, Savolainen M, Isohanni M. Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication: a review. Eur Arch Psychiatry Clin Neurosci 2002; 252(6): 294–298.
   PubMed Web of Science ®Google Scholar
• Bell RC, Farmer S, Ries R, Srebnik D. Metabolic risk factors among medicaid outpatients with schizophrenia receiving second-generation antipsychotics. Psychiatr Serv 2009; 60(12): 1686–1689.
   PubMed Web of Science ®Google Scholar
• Duncan EJ, Woolson SL, Hamer RM, Dunlop BW. Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. Int Clin Psychopharmacol 2009; 24(4): 204–213.
   PubMed Web of Science ®Google Scholar